Depression is improved when low-dose tacrolimus is given to rheumatoid arthritis patients showing an inadequate response to biologic agents

Modern Rheumatology

Volumn 23, Issue 5, 2013, Pages 920-924

  Miwa, Yusuke ^a   Hosaka, Michio ^b   Ohtsuka, Kumiko ^a   Sato, Michihito ^a   Takahashi, Ryo ^a   Wakabayashi, Kuninobu ^a   Odai, Tsuyoshi ^a   Yajima, Nobuyuki ^a   Kasama, Tsuyoshi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Katsuyama Clinic   (Japan)

Author keywords

Biologic agent therapy; Depression; Rheumatoid arthritis; Tacrolimus

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DAS28; DEPRESSION; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; STEROID THERAPY; TREATMENT RESPONSE; ZUNG SELF RATING DEPRESSION SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 84885183036     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0765-z     Document Type: Article

References (24)

1. Iosifescu DV, Babkier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psych Rep. 2004;6:193-201.
2. el-Miedany YM, el-Rasheed AH. Is anxiety a more common disorder than depression in rheumatoid arthritis? Joint Bone Spine. 2002;69:300-6.
3. Dickens C, Jackson J, Tomenson B, Hay E, Creed F. Association of depression and rheumatoid arthritis. Psychosomatics. 2003;44:209-15.
4. Frank RG, Beck NC, Parker JC, Kashani JH, Elliott TR, Haut AE. Depression in rheumatoid arthritis. J Rheumatol. 1988;15:920-5.
5. Japan Rheumatism Support Association. Rheumatism white paper/actual state of rheumatology patients. Tokyo: Japan Rheumatism Support Association; 2005. p. 73.
6. Miwa Y, Yajima N, Shiozawa F, Yoda Y, Hanaoka R, Hanyuda M, et al. Relationship of between psychological factors and arthralgia in patients with rheumatoid arthritis. Mod Rheum. 2002;12:32-6.
7. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of Infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43.
8. Miwa Y, Hosaka M, Matsushima D, Wakabayashi Km Odai T, Matsunawa M et al. Compared to monotherapy with methotextrate, inflixmab treatment is more powerful in improving depression in rheumatoid arthritis patients. Jpn J Psychosom Med. 2008;48:289-95.
9. Miwa Y, Sato M, Takahashi R, Wakabayashi K, Odai T, Isozaki T, et al. Mechanism of improving depression state of rheumatoid arthritis patients by etanercept treatment. Clin Rheumatol. 2010;22:91-8.
10. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparion of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:2153-61.
11. Aramaki T, Kawakami A, Iwamoto N, Fujikawa K, Kawashiri SY, Tamai M, et al. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Mod Rheumatol. 2009;19:652-6.
12. Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol. 2010;37:512-20.
13. Yokota K, Akiyama Y, Asanuma Y, Miyoshi F, Sato K, Mimura T, et al. Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis. Rheumatol Int. 2008;29:459-61.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
15. Japan College of Rheumatology. Guidelines for use of TNF inhibitor treatment for rheumatoid arthritis. Tokyo: Japan College of Rheumatology; 2006.
16. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
17. Fukuda K, Kobayashi S. Guidance for using the Japanese self-rating depression scale. Kyoto: Sankyobo; 1983. pp. 3-15.
18. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, va Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
19. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602.
20. Hocaoglu C, Kural B, AliyazIcIoglu R, Deger O, Cengiz S. IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depression. Metab Brain Dis. 2012. (in press)
21. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Konno K, Tanaka Y. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004;9:1265-73.
22. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of expression of P-glycoprotein on peripheral lymphocytes to steroid-resistance in systemic lupus erythematosus. Arthritis Rheum. 2005;52:1676-83.
23. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380-8.
24. Piilgaad H, Witgen BM, Rasmussen P, Lauritzen M. Cyclosporin A, FK506, and NIM811 ameliorate prolonged CBF reduction and impaired neurovascular coupling after cortical spreading depression. J Cereb Blood Flow Metab. 2011;3:1588-98.